

Patient + Provider Discussion Guide

Tips for talking with your provider about cancer screening and the Galleri[®] test

Proactively discussing cancer screening with your healthcare provider can help them develop a cancer screening plan that is right for you. Routine cancer screening is recommended for only 5 cancers today.

The Galleri[®] multi-cancer early detection test detects a common cancer signal across more than 50 types of cancer, many of which are not commonly screened for today, through a simple blood draw.¹

Used in addition to routine cancer screenings, the Galleri test can increase your chances of finding cancer early, to allow for earlier treatment. Your provider can advise whether the Galleri test is right for you.

The Galleri test does not diagnose cancer or measure your future risk of developing cancer. Additional tests are needed to confirm if cancer is present.

Here are some questions to discuss with your provider

Why is cancer screening and early detection important?

What cancer screening tests are recommended for me?

Am I up to date on my recommended cancer screening tests?

Do I have an increased risk for cancer?

Is the Galleri multi-cancer early detection test right for me?

Important safety information: The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Information for your healthcare provider

The Galleri® test is a multi-cancer early detection test which complements single cancer screenings to increase the chance of early cancer detection. The Galleri test is recommended for patients with an elevated risk for cancer, such as those aged 50 or older.

A revolution in multi-cancer early detection



Around 70% of cancer deaths are caused by cancers not commonly screened for²



Can detect a common cancer signal across over 50 types of cancer through a simple blood draw¹




Test performance supported by rigorous clinical studies with 20,000+ participants



Detects tumor-derived, cell-free DNA (cfDNA) that could indicate the presence of cancer

What you can expect from the Galleri test results

There are two possible test results:



Not all cancers can be detected in the blood. False-positive and false-negative results do occur. See important safety information on prior page.

If the Galleri test is right for your patient, follow these 3 steps to get started:

- 1** **Order the Galleri test** ➤ Visit www.galleri.com/hcp/order to request a Galleri Specimen Collection Kit that will be shipped to your office or call 833-694-2553.
- 2** **Complete a blood draw** ➤ Complete at your office, or at one of our blood draw partners. Patients can visit www.galleri.com/schedule to locate a blood draw partner.
No fasting or advanced preparation is required.
- 3** **Receive the results** ➤ Shared through the GRAIL Provider Portal provider.grail.com/login within **10 business days** after the patient's sample is received in our laboratory.

Learn more at:



www.galleri.com/hcp
customerservice@grail.com



833-MY-GALLERI
(833-694-2553)

1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Ann Oncol.* 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.8062. 2. For US population ages 50-79. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years) Source: Estimated deaths per year in 2021 from American Cancer Society Cancer Facts and Figures 2021. Available at: <http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf>. Data on file GA-2021-0065

Laboratory/Test Information: GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL's clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

©2022 GRAIL, LLC. All Rights Reserved | Galleri® is a registered trademark of GRAIL, LLC. | US-GA-2100012-2